[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3365
56. Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW: Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol; 2009 Jul 10;27(20):3354-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
  • PURPOSE: We studied the incidence, risk factors, treatment, and outcomes of post-transplantation lymphoproliferative disorder (PTLD) that occurred at the University of Michigan since 1964.
  • RESULTS: Diffuse large B-cell lymphoma (n = 43), polymorphic PTLD (n = 10), Hodgkin's lymphoma (n = 7), Burkitts lymphoma (n = 6), plasmacytoma (n = 5), and mucosa-associated lymphoid tissue lymphoma (n = 3) were all over-represented in the SOT population compared with a population sample from the Surveillance, Epidemiology, and End Results (SEER) database; follicular lymphoma (n = 0) was underrepresented.
  • Available histologic analysis of tumor tissue showed that 75% were CD20 positive and that 62% were EBV positive; EBV-positive tumors occurred sooner after SOT than EBV-negative tumors (mean, 29 v 66 months).
  • Extralymphatic disease (79%), poor performance status (68%), elevated lactate dehydrogenase (LDH; 71%), and advanced stage (68%) disease were all common at the time of lymphoma diagnosis.
  • Most of these lymphomas are CD20 positive.
  • Follicular lymphoma is unusual.
  • [MeSH-major] Lymphoma / etiology. Lymphoproliferative Disorders / etiology. Organ Transplantation / adverse effects


57. Sánchez-García J, Serrano J, Gómez P, Martínez F, Martín C, Román-Gómez J, Rodríguez A, Herrera C, García JM, Alvarez MA, Torres A: The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia. Haematologica; 2006 Mar;91(3):340-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
  • BACKGROUND AND OBJECTIVES: The development of graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (SCT) for B-lineage acute lymphoblastic leukemia (B-ALL) is associated with a lower probability of leukemia relapse.
  • However, mechanisms by which this GVHD-associated graft-versus-leukemia effect is exerted are poorly understood.
  • DESIGN AND METHODS: We used multiparameter flow-cytometry to quantify pro-B (CD19+CD10+CD34+), pre-B (CD19+CD10+CD34-) precursors and malignant lymphoblasts identified by leukemia-associated markers in 161 prospective marrow samples from 39 consecutive B-ALL patients after allogeneic SCT.
  • RESULTS: Acute GVHD of grades II-IV is associated with a strong inhibition of normal donor-derived pro-B and pre-B precursors at days +30 and +60 post-SCT.
  • Patients who develop chronic GVHD have lower percentages of marrow B-cell precursors during the first year after SCT.
  • Likewise, recipient-derived leukemia B cells were absent at days +30 and +60 in patients with acute GVHD grades II-IV and were less likely to be detected in patients with chronic GVHD.
  • Induction of GVHD as treatment of increasing amounts of leukemia cells causes inhibition of both normal and malignant B compartments even in the absence of steroid therapy.
  • INTERPRETATION AND CONCLUSIONS: We conclude that the development of GVHD after allogeneic SCT is associated with a non-specific inhibition of B-lymphopoiesis.
  • [MeSH-major] Burkitt Lymphoma / immunology. Graft vs Host Disease / immunology. Hematopoietic Stem Cells / cytology. Hematopoietic Stem Cells / pathology. Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Cell Lineage. Child. Child, Preschool. Chronic Disease. Female. Humans. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Prospective Studies. Transplantation, Homologous


58. Tanaka G, Kanaji S, Hirano A, Arima K, Shinagawa A, Goda C, Yasunaga S, Ikizawa K, Yanagihara Y, Kubo M, Kuriyama-Fujii Y, Sugita Y, Inokuchi A, Izuhara K: Induction and activation of the aryl hydrocarbon receptor by IL-4 in B cells. Int Immunol; 2005 Jun;17(6):797-805
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We identified IL-4- or IL-13-inducible genes in a human Burkitt lymphoma cell line, DND-39, using microarray technology, in which the AHR gene was included.
  • AhR activated by IL-4 caused expression of a xenobiotic-metabolizing gene, CYP1A1, and TCDD synergistically acted on the induction of this gene by IL-4.
  • [MeSH-minor] Animals. Burkitt Lymphoma / enzymology. Burkitt Lymphoma / genetics. Burkitt Lymphoma / metabolism. Cell Line. Cell Line, Tumor. Cell Nucleus / drug effects. Cell Nucleus / metabolism. Cytochrome P-450 CYP1A1 / metabolism. Environmental Pollutants / toxicity. Humans. Interleukin-13 / pharmacology. Lymphoma, B-Cell / enzymology. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / metabolism. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Plasmids. Tetrachlorodibenzodioxin / toxicity. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15899923.001).
  • [ISSN] 0953-8178
  • [Journal-full-title] International immunology
  • [ISO-abbreviation] Int. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Environmental Pollutants; 0 / Interleukin-13; 0 / Receptors, Aryl Hydrocarbon; 207137-56-2 / Interleukin-4; DO80M48B6O / Tetrachlorodibenzodioxin; EC 1.14.14.1 / Cytochrome P-450 CYP1A1
  •  go-up   go-down


59. Asito AS, Piriou E, Odada PS, Fiore N, Middeldorp JM, Long C, Dutta S, Lanar DE, Jura WG, Ouma C, Otieno JA, Moormann AM, Rochford R: Elevated anti-Zta IgG levels and EBV viral load are associated with site of tumor presentation in endemic Burkitt's lymphoma patients: a case control study. Infect Agent Cancer; 2010;5:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated anti-Zta IgG levels and EBV viral load are associated with site of tumor presentation in endemic Burkitt's lymphoma patients: a case control study.
  • BACKGROUND: Endemic Burkitt's lymphoma (BL) is an extranodal tumor appearing predominantly in the jaw in younger children while abdominal tumors predominate with increasing age.
  • Previous studies have identified elevated levels of antibodies to Plasmodium falciparum schizont extracts and Epstein-Barr virus (EBV) viral capsid antigens (VCA) in endemic BL relative to malaria exposed controls.
  • However, these studies have neither determined if there were any differences based on the site of clinical presentation of the tumor nor examined a broader panel of EBV and P. falciparum antigens.
  • METHODS: We used a suspension bead Luminex assay to measure the IgG levels against EBV antigens, VCA, EAd, EBNA-1 and Zta as well as P. falciparum MSP-1, LSA-1, and AMA-1 antigens in children with BL (n = 32) and in population-based age-and sex-matched controls (n = 25) from a malaria endemic region in Western Kenya with high incidence of BL.
  • RESULTS: Relative to healthy controls, BL patients had significantly increased anti-Zta (p = 0.0017) and VCA IgG levels (p < 0.0001) and plasma EBV viral loads (p < 0.0001).
  • In contrast, comparable IgG levels to all P. falciparum antigens tested were observed in BL patients compared to controls.
  • Interestingly, when we grouped BL patients into those presenting with abdominal tumors or with jaw tumors, we observed significantly higher levels of anti-Zta IgG levels (p < 0.0065) and plasma EBV viral loads (p < 0.033) in patients with abdominal tumors compared to patients with jaw tumors.
  • CONCLUSION: Elevated antibodies to Zta and elevated plasma EBV viral load could be relevant biomarkers for BL and could also be used to confirm BL presenting in the abdominal region.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Cancer Biol. 2009 Dec;19(6):377-88 [19619657.001]
  • [Cites] J Gen Virol. 1995 Jun;76 ( Pt 6):1393-400 [7540196.001]
  • [Cites] J Infect Dis. 1994 Jul;170(1):13-9 [8014488.001]
  • [Cites] Cancer. 1980 Mar 15;45(6):1507-15 [6244085.001]
  • [Cites] Nature. 1978 Aug 24;274(5673):756-61 [210392.001]
  • [Cites] Lancet. 1977 Feb 12;1(8007):335-8 [64861.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Arch Pathol Lab Med. 2004 May;128(5):549-52 [15086279.001]
  • [Cites] Cytometry. 2002 Oct 15;50(5):239-42 [12360572.001]
  • [Cites] Int J Cancer. 2002 Jun 10;99(5):635-43 [12115495.001]
  • [Cites] Int J Cancer. 2009 Apr 1;124(7):1721-6 [19089927.001]
  • [Cites] Nat Rev Microbiol. 2008 Dec;6(12):913-24 [19008891.001]
  • [Cites] Clin Vaccine Immunol. 2008 Nov;15(11):1684-8 [18768669.001]
  • [Cites] Int J Cancer. 2008 Dec 1;123(11):2658-63 [18767045.001]
  • [Cites] PLoS One. 2008;3(6):e2505 [18560562.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1319-23 [18000823.001]
  • [Cites] J Clin Virol. 2008 Feb;41(2):96-103 [18024156.001]
  • [Cites] AIDS. 2007 Oct 18;21(16):2141-9 [18090040.001]
  • [Cites] Trop Med Int Health. 2007 Aug;12(8):936-43 [17697088.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):121-7 [17019706.001]
  • [Cites] Singapore Med J. 2006 Sep;47(9):803-7 [16924363.001]
  • [Cites] J Infect Dis. 2005 Apr 15;191(8):1233-8 [15776368.001]
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):4059-66 [15736452.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]
  • [Cites] East Afr Med J. 2004 Aug;(8 Suppl):S111-6 [15622609.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):6-11 [10077144.001]
  • [Cites] J Med Virol. 1999 Apr;57(4):383-9 [10089051.001]
  • [Cites] J Infect Dis. 1999 May;179(5):1108-15 [10191211.001]
  • [Cites] Ann Med. 1998 Jun;30(3):249-59 [9677010.001]
  • [Cites] Pediatr Pathol Lab Med. 1997 May-Jun;17(3):391-400 [9185219.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Blood. 1995 Jul 15;86(2):659-65 [7605996.001]
  • [Cites] J Med Virol. 2009 Jun;81(6):1088-93 [19382256.001]
  • (PMID = 20667138.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102667
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2923120
  •  go-up   go-down


60. Kangwansupamonkon W, Lauruengtana V, Surassmo S, Ruktanonchai U: Antibacterial effect of apatite-coated titanium dioxide for textiles applications. Nanomedicine; 2009 Jun;5(2):240-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its antibacterial performance was observed under black light, visible light, and dark conditions.
  • The effect of irradiation source on antimicrobial activity of coated cotton fabrics was examined, wherein black-light irradiation demonstrated higher antibacterial activity than either visible-light irradiation or dark conditions.
  • Our findings suggest that the presence of apatite-coated TiO2 shows antibacterial activity in the presence of black light or visible light, suggesting its potential use in reducing the risk of microorganism transmission for textile applications.

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • Hazardous Substances Data Bank. TITANIUM DIOXIDE .
  • Hazardous Substances Data Bank. TITANIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223243.001).
  • [ISSN] 1549-9642
  • [Journal-full-title] Nanomedicine : nanotechnology, biology, and medicine
  • [ISO-abbreviation] Nanomedicine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Apatites; 0 / Coated Materials, Biocompatible; 15FIX9V2JP / titanium dioxide; D1JT611TNE / Titanium
  •  go-up   go-down


61. Sun BW, Shi GS, Zhang P, Zou XQ, Chen X: [Inhibitive effect of exogenous carbon monoxide-releasing molecules 2 on tissue factor expression in sepsis]. Zhonghua Shao Shang Za Zhi; 2009 Apr;25(2):111-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty-five C57 BL/6 male mice were randomly divided into NC (without treatment, n = 5), CLP (n = 5) and CLP + CORM-2 (with treatment of 8 mg/kg CROM-2 after CLP, n = 5) groups.

  • MedlinePlus Health Information. consumer health - Sepsis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19799035.001).
  • [ISSN] 1009-2587
  • [Journal-full-title] Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns
  • [ISO-abbreviation] Zhonghua Shao Shang Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Lipoproteins; 0 / NF-kappa B; 0 / Organometallic Compounds; 0 / lipoprotein-associated coagulation inhibitor; 0 / tricarbonyldichlororuthenium (II) dimer; 9035-58-9 / Thromboplastin
  •  go-up   go-down


62. D'Alessandro DM, Dinolfo PH, Davies MS, Hupp JT, Keene FR: Underlying spin-orbit coupling structure of intervalence charge transfer bands in dinuclear polypyridyl complexes of ruthenium and osmium. Inorg Chem; 2006 Apr 17;45(8):3261-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mixed-valence systems meso- and rac-[{M(bpy)2}2(mu-BL)]5+ {M = Ru, Os; BL = a series of polypyridyl bridging ligands such as 2,3-bis(2-pyridyl)benzoquinoxaline (dpb)} are characterized by multiple intervalence charge transfer (IVCT) and interconfigurational (IC) bands in the mid-infrared and near-infrared (NIR) regions.
  • An increase in the separation between the IC bands as BL is varied reflects the increase in the degree of electronic coupling through the series of ruthenium and osmium complexes.
  • Stark effect measurements reveal small dipole moment changes accompanying IVCT excitation in support of the localized-to-delocalized or delocalized classification for the dinuclear ruthenium and osmium systems.


63. Kino K, Nakazawa Y, Yagasaki M: Dipeptide synthesis by L-amino acid ligase from Ralstonia solanacearum. Biochem Biophys Res Commun; 2008 Jul 4;371(3):536-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, a novel method for effective production of dipeptides using l-amino acid alpha-ligase (Lal) is presented.
  • Lal, which is only identified in Bacillus subtilis, catalyzes dipeptide synthesis from unprotected amino acids in an ATP-dependent manner.
  • However, not all the dipeptide can be synthesized by Lal from B. subtilis (BsLal) due to its substrate specificity.
  • Here, we attempted to find a novel Lal exhibiting different substrate specificity from BsLal.
  • By in silico screening based on the amino acid sequence of BsLal, RSp1486a an unknown protein from Ralstonia solanacearum was found to show the Lal activity.

  • COS Scholar Universe. author profiles.
  • National BioResource Project. culture/stock collections - NBRP resources .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18445480.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dipeptides; 0 / Plant Proteins; EC 6.3.2.- / Peptide Synthases
  •  go-up   go-down


6
Advertisement
4. Coyaud E, Struski S, Prade N, Familiades J, Eichner R, Quelen C, Bousquet M, Mugneret F, Talmant P, Pages MP, Lefebvre C, Penther D, Lippert E, Nadal N, Taviaux S, Poppe B, Luquet I, Baranger L, Eclache V, Radford I, Barin C, Mozziconacci MJ, Lafage-Pochitaloff M, Antoine-Poirel H, Charrin C, Perot C, Terre C, Brousset P, Dastugue N, Broccardo C: Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study. Blood; 2010 Apr 15;115(15):3089-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study.
  • PAX5 is the main target of somatic mutations in acute B lymphoblastic leukemia (B-ALL).
  • Furthermore, malignant cells carrying PAX5 fusion genes displayed a simple karyotype.
  • In addition, PAX5 deletion was observed in 60% of B-ALL with 9p alterations.
  • Our data shed more light on the high variability of PAX5 alterations in B-ALL.
  • Therefore, it is probable that gene fusions occur early, whereas deletions should be regarded as a late/secondary event.
  • [MeSH-major] B-Cell-Specific Activator Protein / genetics. Cytogenetic Analysis. Mutation / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20160164.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Oncogene Proteins, Fusion; 0 / PAX5 protein, human
  •  go-up   go-down


65. Zhao J, Yang CH, Hu M, Liu ZQ: [Absorption characteristics of ginsenoside Rb2 in Caco-2 cell monolayer]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Dec;29(12):2387-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Absorption characteristics of ginsenoside Rb2 in Caco-2 cell monolayer].
  • OBJECTIVE: To determine the concentration of ginsenoside Rb(2) and study the absorption characteristics of ginsenoside Rb(2) in Caco-2 cell monolayer.
  • RESULTS: P(app(AP-BL)) was 3.27 x 10(-7) cm.s(-1), P(app(BL-AP)) was 3.16 x 10(-6) cm.s(-1), and the efflux ratio (P(app(BL-AP))/P(app(AP-BL))) was 9.63.
  • CONCLUSION: The absorption characteristics of ginsenoside Rb(2) in Caco-2 cell model have been demonstrated.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20034882.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ginsenosides; 11021-13-9 / ginsenoside Rb2
  •  go-up   go-down


66. Hariharan S, Gunda S, Mishra GP, Pal D, Mitra AK: Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids. Pharm Res; 2009 May;26(5):1270-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Bi-directional transport of erythromycin across MDCK-MDR1 and MDCK-MRP2 cells showed significant difference between BL-AP and AP-BL permeability, suggesting that erythromycin is a substrate for P-gp and MRP2.

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Erythromycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18958406.001).
  • [ISSN] 1573-904X
  • [Journal-full-title] Pharmaceutical research
  • [ISO-abbreviation] Pharm. Res.
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / R01 EY009171; United States / NEI NIH HHS / EY / R01 EY010659; United States / NEI NIH HHS / EY / R01EY09171-14; United States / NEI NIH HHS / EY / R01EY10659-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 63937KV33D / Erythromycin
  • [Other-IDs] NLM/ NIHMS680905; NLM/ PMC4516224
  •  go-up   go-down


67. Pereira JA, Pleguezuelos E, Merí A, Molina-Ros A, Molina-Tomás MC, Masdeu C: Effectiveness of using blended learning strategies for teaching and learning human anatomy. Med Educ; 2007 Feb;41(2):189-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Blended learning strategies were employed in 1 group (BL group, n = 69); the other (TT group; n = 65) received traditional teaching aided by complementary material that could be accessed on the Internet.
  • RESULTS: The average marks presented statistically significant differences (BL 6.3 versus TT 5.0; P < 0.0001).
  • The percentage pass rate for the subject in the first call was higher in the BL group (87.9% versus 71.4%; P = 0.02), reflecting a lower incidence of students who failed to sit the examination (BL 4.3% versus TT 13.8%; P = 0.05).
  • [MeSH-major] Anatomy / education. Clinical Competence / standards. Education, Medical, Undergraduate / methods. Learning. Teaching / methods

  • MedlinePlus Health Information. consumer health - Anatomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17269953.001).
  • [ISSN] 0308-0110
  • [Journal-full-title] Medical education
  • [ISO-abbreviation] Med Educ
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


68. Meyer M, Stähler J, Kusmierek DO, Wolf M, Bovensiepen U: Determination of the electron's solvation site on D2O/Cu(111) using Xe overlayers and femtosecond photoelectron spectroscopy. Phys Chem Chem Phys; 2008 Aug 28;10(32):4932-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determination of the electron's solvation site on D2O/Cu(111) using Xe overlayers and femtosecond photoelectron spectroscopy.
  • We investigate the binding site of solvated electrons in amorphous D(2)O clusters and D(2)O wetting layers adsorbed on Cu(111) by means of two-photon photoelectron (2PPE) spectroscopy.
  • We employ an empirical model calculation to analyse the rate of electron transfer back to the substrate and the energetic stabilization of the solvated electrons, which allows further insight into the binding site for clusters.
  • Therefore, we attribute the transition from surface- to bulk-solvation to the coalescence of the clusters to a closed ice film occurring at a nominal coverage of 2-3 BL, while the distance of the binding sites to the metal-ice interface is maintained.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688537.001).
  • [ISSN] 1463-9076
  • [Journal-full-title] Physical chemistry chemical physics : PCCP
  • [ISO-abbreviation] Phys Chem Chem Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


69. Gal SZ, Wang J: [Clinical observation on drug-separated moxibustion at the navel for anti-aging]. Zhongguo Zhen Jiu; 2007 Jun;27(6):398-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical observation on drug-separated moxibustion at the navel for anti-aging].
  • OBJECTIVE; To observe clinical therapeutic effect and the mechanism of drug-separated moxibustion at the navel for delaying aging.
  • The group of drug-separated moxibustion at the navel (n=30) were treated with drug-separated moxibustion at the navel, twice each week; the acupuncture group (n=21) with acupuncture at Shenshu (BL 23) and Taixi (KI 3) as main points once each day; the western medicine group (n=20) with oral administration of vitamin E capsules, 0.
  • Their clinical therapeutic effects, and changes of cumulative scores, serum SOD activities and MDA contents after treatment were compared among the 3 groups.
  • RESULTS: After treatment, clinical symptoms in the 3 groups very significantly improved (P < 0.01), with the group of drug-separated moxibustion at the navel more significantly improved (P < 0.01); in the 3 groups, SOD activities significantly increased (P < 0.01) and serum MDA contents significantly decreased (P < 0.01), and SOD activity and MDA content in the group of drug-separated moxibustion at the navel were not significantly different from those in the acupuncture group (P > 0.05), but significantly different from those in the western medicine group (P < 0.05).

  • MedlinePlus Health Information. consumer health - Acupuncture.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17663099.001).
  • [ISSN] 0255-2930
  • [Journal-full-title] Zhongguo zhen jiu = Chinese acupuncture & moxibustion
  • [ISO-abbreviation] Zhongguo Zhen Jiu
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 4Y8F71G49Q / Malondialdehyde; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


70. Schepel SA, Fox AJ, Miyauchi JT, Sou T, Yang JD, Lau K, Blum AW, Nicholson LK, Tiburcy F, Nachman RJ, Piermarini PM, Beyenbach KW: The single kinin receptor signals to separate and independent physiological pathways in Malpighian tubules of the yellow fever mosquito. Am J Physiol Regul Integr Comp Physiol; 2010 Aug;299(2):R612-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Now using the kinins of Aedes (the aedeskinins), we have found that in isolated Aedes Malpighian tubules all three aedeskinins (1 microM) significantly 1) increased the rate of fluid secretion (V(S)), 2) hyperpolarized the basolateral membrane voltage (V(bl)), and 3) decreased the input resistance (R(in)) of principal cells, consistent with the known increase in the Cl(-) conductance of the paracellular pathway in Aedes Malpighian tubules.
  • While the three aedeskinins triggered effects on V(bl), R(in), and V(S), synthetic kinin analogs, which contain modifications of the COOH-terminal amide pentapeptide core sequence critical for biological activity, displayed variable effects.
  • For example, kinin analog 1578 significantly stimulated V(S) but had no effect on V(bl) and R(in), whereas kinin analog 1708 had no effect on V(S) but significantly affected V(bl) and R(in).

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. SODIUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Biol. 1999 Dec;202(Pt 24):3667-76 [10574744.001]
  • [Cites] Am J Physiol. 1985 Mar;248(3 Pt 2):R339-45 [2579589.001]
  • [Cites] J Biol Chem. 2000 May 5;275(18):13727-36 [10788493.001]
  • [Cites] J Comp Neurol. 2000 Sep 11;425(1):45-57 [10940941.001]
  • [Cites] Am J Physiol Renal Physiol. 2000 Oct;279(4):F747-54 [10997925.001]
  • [Cites] Pflugers Arch. 1985;405 Suppl 1:S17-22 [4088834.001]
  • [Cites] Life Sci. 1989;44(18):1259-66 [2716471.001]
  • [Cites] Methods Enzymol. 1990;191:167-226 [2074756.001]
  • [Cites] Am J Physiol. 1991 Sep;261(3 Pt 1):C521-9 [1653525.001]
  • [Cites] Am J Physiol. 1992 Sep;263(3 Pt 2):R609-14 [1415649.001]
  • [Cites] J Membr Biol. 1993 Feb;132(1):63-76 [8459448.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Jul 29;202(2):715-9 [8048942.001]
  • [Cites] Peptides. 1995;16(1):95-104 [7716080.001]
  • [Cites] J Biol Chem. 1995 Sep 15;270(37):21722-8 [7665591.001]
  • [Cites] J Exp Biol. 1996 May;199(Pt 5):1163-75 [8786336.001]
  • [Cites] Peptides. 1996;17(2):327-36 [8801541.001]
  • [Cites] J Biol Chem. 1997 Apr 18;272(16):10402-7 [9099680.001]
  • [Cites] Ann N Y Acad Sci. 1997 Apr 24;814:342-5 [9160988.001]
  • [Cites] Physiol Rev. 1997 Oct;77(4):963-1032 [9354810.001]
  • [Cites] Peptides. 1998;19(3):469-80 [9533634.001]
  • [Cites] J Exp Biol. 1998 Jun;201(Pt 11):1753-62 [9576886.001]
  • [Cites] Mol Pharmacol. 1998 Jul;54(1):94-104 [9658194.001]
  • [Cites] Cell Tissue Res. 1998 Dec;294(3):549-60 [9799471.001]
  • [Cites] Peptides. 1999;20(1):1-10 [10098618.001]
  • [Cites] J Exp Biol. 2004 Dec;207(Pt 26):4573-86 [15579553.001]
  • [Cites] Insect Mol Biol. 2005 Jan;14(1):55-67 [15663775.001]
  • [Cites] Mol Interv. 2005 Jun;5(3):154-7 [15994454.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Nov;289(5):C1261-7 [15987771.001]
  • [Cites] Arch Insect Biochem Physiol. 2006 Jul;62(3):128-40 [16783824.001]
  • [Cites] Biopolymers. 2007;88(1):76-82 [17117460.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10691-6 [17563389.001]
  • [Cites] Gen Comp Endocrinol. 2007 Jun-Jul;152(2-3):332-8 [17400222.001]
  • [Cites] Nature. 2007 Nov 15;450(7168):383-7 [17952055.001]
  • [Cites] J Exp Biol. 2008 Feb;211(Pt 3):409-22 [18203997.001]
  • [Cites] Peptides. 2008 Feb;29(2):302-9 [18207610.001]
  • [Cites] Gen Comp Endocrinol. 2009 May 15;162(1):122-8 [18983996.001]
  • [Cites] Biophys J. 2009 Oct 21;97(8):2202-11 [19843452.001]
  • [Cites] J Exp Biol. 2009 Dec;212(Pt 23):3802-9 [19915121.001]
  • [Cites] Insect Biochem Mol Biol. 2000 Dec;30(12):1147-59 [11044661.001]
  • [Cites] J Physiol Paris. 2000 May-Aug;94(3-4):185-92 [11087995.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):5375-83 [11087732.001]
  • [Cites] J Exp Biol. 2001 Sep;204(Pt 17):3075-84 [11551995.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2001 Nov;281(5):E1015-21 [11595658.001]
  • [Cites] Am J Physiol Renal Physiol. 2002 Sep;283(3):F499-508 [12167601.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Sep;302(3):957-62 [12183652.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38810-7 [12163486.001]
  • [Cites] J Exp Biol. 2003 Jan;206(Pt 2):233-43 [12477894.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Mar;284(3):C718-28 [12444020.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2003 Sep;12(5):543-50 [12920403.001]
  • [Cites] J Exp Biol. 2004 Jan;207(Pt 3):519-26 [14691099.001]
  • [Cites] Ann N Y Acad Sci. 1999;897:361-73 [10676463.001]
  • (PMID = 20538895.001).
  • [ISSN] 1522-1490
  • [Journal-full-title] American journal of physiology. Regulatory, integrative and comparative physiology
  • [ISO-abbreviation] Am. J. Physiol. Regul. Integr. Comp. Physiol.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / R01 AG029385
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chlorides; 0 / Insect Proteins; 0 / Kinins; 0 / Receptors, G-Protein-Coupled; 9NEZ333N27 / Sodium; RWP5GA015D / Potassium
  • [Other-IDs] NLM/ PMC3774469
  •  go-up   go-down


71. Futagbi G, Welbeck JE, Tetteh JK, Hviid L, Akanmori BD: Selective activation of TCR-gammadelta+ cells in endemic Burkitt's lymphoma. Malar J; 2007;6:69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective activation of TCR-gammadelta+ cells in endemic Burkitt's lymphoma.
  • BACKGROUND: The overlap in geographical distribution of Plasmodium falciparum malaria and endemic Burkitt's lymphoma (eBL)--an aggressive Epstein-Barr virus (EBV)-associated B-cell tumour occurring almost exclusively in the tropics--strongly suggests a link between the two diseases.
  • It is suspected that the polyclonal B-cell activation in P. falciparum malaria may precipitate a breakdown in homeostatic T-cell control of EBV-immortalized B-cell proliferation.
  • Previous studies have suggested that a particular T-cell subset, characterized by expression of Vdelta1+ gammadelta T-cell receptors, is important for maintaining B-cell homeostasis, both in P. falciparum- exposed populations and in individuals subject to polyclonal B-cell activation of other aetiology.
  • The objective of the present study was, therefore, to characterize lymphocyte phenotypes and to investigate possible differences in T-cell subset composition and activation status in P. falciparum-exposed Ghanaian children with and without eBL.
  • METHODS: Venous blood samples in heparin from 21 eBL patients (mean age: 7.0 years; range: 3-11 years), referred to the Burkitt's Tumour Centre at Korle-Bu Teaching Hospital, Accra and 15 healthy, age and sex matched children, were stained with fluorescein isothiocyanate (FITC)-, phycoerythrin (PE)-, R-phycoerythrin (RPE)- and RPE-Cy5-conjugated antibodies (CD3, CD4, CD8, CD25, CD69, CD95, HLA-DR, TCR-gammadelta, Vdelta1, Vdelta3, Vgamma9 and B-cells) and acquired on a flow cytometer.
  • The data supports the hypothesis of a regulatory role for Vdelta1+ TcR-gammadelta T-cells in maintaining B-cell homeostasis and provides insights into the pathogenesis of eBL.
  • [MeSH-major] Burkitt Lymphoma / immunology. Lymphocyte Activation. Malaria, Falciparum / complications. Malaria, Falciparum / immunology. Receptors, Antigen, T-Cell, gamma-delta / metabolism. T-Lymphocyte Subsets / immunology

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEMS Microbiol Immunol. 1991 Aug;3(4):219-27 [1931134.001]
  • [Cites] J Immunol. 1992 Dec 15;149(12):3984-9 [1334108.001]
  • [Cites] J Immunol Methods. 1993 Jan 4;157(1-2):135-42 [8423356.001]
  • [Cites] Am J Trop Med Hyg. 1994 Sep;51(3):372-9 [7524374.001]
  • [Cites] Eur J Immunol. 1994 Dec;24(12):3199-204 [7528674.001]
  • [Cites] J Immunol. 1997 Jan 1;158(1):464-74 [8977224.001]
  • [Cites] Infect Immun. 1996 Oct;64(10):4359-62 [8926112.001]
  • [Cites] Pediatr Hematol Oncol. 1999 Mar-Apr;16(2):149-58 [10100275.001]
  • [Cites] Am J Trop Med Hyg. 1991 May;44(5):571-7 [2063961.001]
  • [Cites] Int Immunol. 2000 Jun;12(6):797-805 [10837407.001]
  • [Cites] Infect Immun. 2001 May;69(5):3190-6 [11292740.001]
  • [Cites] J Natl Cancer Inst. 1969 Jan;42(1):19-28 [4303830.001]
  • [Cites] Am J Med. 1970 Mar;48(3):279-85 [4190958.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1977;71(5):408-10 [304268.001]
  • [Cites] Clin Exp Immunol. 1978 Apr;32(1):41-5 [352584.001]
  • [Cites] Nature. 1978 Aug 24;274(5673):756-61 [210392.001]
  • [Cites] Int J Cancer. 1978 Dec;22(6):662-8 [214405.001]
  • [Cites] Nature. 1984 Nov 29-Dec 5;312(5993):398 [6095098.001]
  • [Cites] Nature. 1984 Nov 29-Dec 5;312(5993):449-50 [6095104.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1262-74 [3114436.001]
  • [Cites] Eur J Immunol. 1991 May;21(5):1249-53 [1674690.001]
  • (PMID = 17521425.001).
  • [ISSN] 1475-2875
  • [Journal-full-title] Malaria journal
  • [ISO-abbreviation] Malar. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, gamma-delta
  • [Other-IDs] NLM/ PMC1894981
  •  go-up   go-down


72. Cohn E, Ossowski L, Bertran S, Marzan C, Farias EF: RARα1 control of mammary gland ductal morphogenesis and wnt1-tumorigenesis. Breast Cancer Res; 2010;12(5):R79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used whole mounts analysis, stem cells/progenitor quantification, mammary gland repopulation, Q-PCR, test of tumor-free survival, tumor fragments and cell transplantation.
  • RESULTS: In 2 genetic backgrounds (129/Bl-6 and FVB) the neo-natal RARα1/KO-mammary epithelial tree was 2-fold larger and the pubertal tree had 2-fold more branch points and 5-fold more mature end buds, a phenotype that was predominantly epithelial cell autonomous.
  • The stem/progenitor compartment of the RARα1/KO mammary, defined as CD24(low)/ALDH(high activity) was increased by a median 1.7 fold, but the mammary stem cell (MaSC)-containing compartment, (CD24(low)/CD29(high)), was larger (~1.5 fold) in the wt-glands, and the mammary repopulating ability of the wt-gland epithelium was ~2-fold greater.
  • The tumor-free survival of RARα1/KO-wnt1 mice was significantly (p=0.0002, Kaplan Meier) longer, the in vivo growth of RARα1/KO-wnt1 transplanted tumor fragments was significantly (p=0.01) slower and RARα1/KO-wnt1 tumors cell suspension produced tumors after much longer latency.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2006 Jan 5;439(7072):84-8 [16397499.001]
  • [Cites] Dev Dyn. 2005 Dec;234(4):892-9 [16217742.001]
  • [Cites] Breast Cancer Res. 2006;8(1):R7 [16417656.001]
  • [Cites] Breast Cancer Res. 2006;8(1):201 [16524451.001]
  • [Cites] Mol Cancer. 2006;5:12 [16563162.001]
  • [Cites] J Exp Med. 2006 May 15;203(5):1283-93 [16682494.001]
  • [Cites] Nature. 2006 May 25;441(7092):475-82 [16598206.001]
  • [Cites] Nature. 2006 May 25;441(7092):518-22 [16633340.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2006 Oct;11(3-4):213-28 [17120154.001]
  • [Cites] Development. 2007 Mar;134(6):1231-42 [17287253.001]
  • [Cites] Vitam Horm. 2007;75:69-95 [17368312.001]
  • [Cites] Transgenic Res. 2007 Apr;16(2):193-201 [17206489.001]
  • [Cites] Stem Cell Rev. 2007 Jun;3(2):124-36 [17873345.001]
  • [Cites] J Cell Biochem. 2007 Nov 1;102(4):886-98 [17902161.001]
  • [Cites] Oncogene. 2007 Nov 29;26(54):7526-34 [17546050.001]
  • [Cites] Cell Mol Life Sci. 2007 Dec;64(24):3248-60 [17955177.001]
  • [Cites] Stem Cells. 2008 Feb;26(2):364-71 [17975224.001]
  • [Cites] Development. 2008 Mar;135(6):995-1003 [18296651.001]
  • [Cites] Breast Cancer Res. 2008;10(3):402; author reply 403 [18522763.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7711-7 [18829523.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):555-67 [18371393.001]
  • [Cites] J Pathol. 2009 Jan;217(2):229-41 [19009588.001]
  • [Cites] Nucl Recept Signal. 2009;7:e002 [19381305.001]
  • [Cites] Nucl Recept Signal. 2009;7:e006 [19471585.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2008;73:469-78 [19022771.001]
  • [Cites] BMC Cancer. 2009;9:325 [19751508.001]
  • [Cites] Genes Dev. 2009 Nov 15;23(22):2563-77 [19933147.001]
  • [Cites] Oncogene. 2010 Jun 24;29(25):3665-76 [20453882.001]
  • [Cites] Curr Biol. 1999 Dec 2;9(23):1415-8 [10607566.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):1002-9 [10713683.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 15;92(6):475-80 [10716965.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3044-9 [10737785.001]
  • [Cites] Nat Med. 2000 Nov;6(11):1235-40 [11062534.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1439-47 [12368216.001]
  • [Cites] Genes Dev. 2003 May 15;17(10):1253-70 [12756227.001]
  • [Cites] Cell Prolif. 2003 Oct;36 Suppl 1:59-72 [14521516.001]
  • [Cites] J Biol Chem. 2003 Nov 28;278(48):48137-45 [12972427.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15853-8 [14668450.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4158-63 [15020770.001]
  • [Cites] Fed Proc. 1976 May 1;35(6):1332-8 [770206.001]
  • [Cites] Nutr Rev. 1978 Jan;36(1):16-9 [342996.001]
  • [Cites] Exp Cell Biol. 1988;56(5):254-63 [3229553.001]
  • [Cites] Prev Med. 1989 Sep;18(5):576-91 [2694156.001]
  • [Cites] Biomed Pharmacother. 1991;45(4-5):145-56 [1657236.001]
  • [Cites] Development. 1994 Oct;120(10):2749-71 [7607068.001]
  • [Cites] J Cell Biochem Suppl. 1994;20:32-54 [7616752.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):1138-49 [8622658.001]
  • [Cites] Int J Cancer. 1997 Mar 4;70(5):619-27 [9052765.001]
  • [Cites] Cell Growth Differ. 1997 Jun;8(6):631-41 [9185997.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2642-50 [9205071.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1741-9 [9403724.001]
  • [Cites] Expert Rev Mol Med. 2004 Nov 30;6(25):1-23 [15569396.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jan;10(1):17-24 [15886883.001]
  • [Cites] Endocrinology. 2005 Aug;146(8):3577-88 [15878961.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8193-9 [16166294.001]
  • [Cites] Nature. 2006 Feb 23;439(7079):993-7 [16395311.001]
  • (PMID = 20923554.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA54273
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / Antigens, CD29; 0 / Isoenzymes; 0 / Receptors, Retinoic Acid; 0 / Wnt1 Protein; 0 / Wnt1 protein, mouse; 0 / retinoic acid receptor alpha; EC 1.2.1.- / aldehyde dehydrogenase 1; EC 1.2.1.36 / Retinal Dehydrogenase
  •  go-up   go-down


73. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, Horsman DE, Gascoyne RD: MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood; 2009 Oct 22;114(17):3533-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
  • Approximately 5% to 10% of diffuse large B-cell lymphomas (DLBCLs) harbor an MYC oncogene rearrangement (MYC+).
  • The diagnosis of MYC+ DLBCL is likely underappreciated; and given the lack of defining risk factors, fluorescence in situ hybridization for MYC rearrangements should be performed in all patients with DLBCL.
  • Treatment regimens similar to those used in Burkitt lymphoma may be more appropriate in this patient population and need to be prospectively tested.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gene Rearrangement. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-myc / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / genetics. Prednisone / administration & dosage. Prognosis. Rituximab. Treatment Outcome. Vincristine / administration & dosage. Young Adult


74. Caron G, Le Gallou S, Lamy T, Tarte K, Fest T: CXCR4 expression functionally discriminates centroblasts versus centrocytes within human germinal center B cells. J Immunol; 2009 Jun 15;182(12):7595-602
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The rapidly dividing centroblasts and the nondividing centrocytes represent the two major B cell subsets present in germinal center and also the most common normal counterparts for a majority of lymphomas.
  • By gene set enrichment analysis we demonstrated that the centroblastic gene expression signature was significantly enriched in Burkitt's lymphomas.
  • Collectively, our findings show that CXCR4 expression can properly separate human centroblasts from centrocytes and offer now the possibility to have purified normal counterparts of mature B cell-derived malignancies.
  • [MeSH-major] B-Lymphocytes / cytology. B-Lymphocytes / immunology. Cell Cycle. Cell Differentiation / immunology. Germinal Center / cytology. Germinal Center / immunology. Receptors, CXCR4 / immunology
  • [MeSH-minor] Cell Membrane / immunology. Cell Membrane / metabolism. Cells, Cultured. Gene Expression Profiling. Gene Expression Regulation / immunology. Humans. Immunoglobulin G / immunology. Transcription, Genetic / genetics. Trihexosylceramides / immunology

  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19494283.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Receptors, CXCR4; 0 / Trihexosylceramides; 71965-57-6 / globotriaosylceramide
  •  go-up   go-down


75. Santamaría-Quesada C, Vargas M, Venegas P, Calvo M, Obando C, Valverde B, Cartín W, Carrillo JM, Jimenez R, González M: Molecular and epidemiologic findings of childhood acute leukemia in Costa Rica. J Pediatr Hematol Oncol; 2009 Feb;31(2):131-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular and epidemiologic findings of childhood acute leukemia in Costa Rica.
  • In Central America, nearly 70% of pediatric cancer is related to hemato-oncologic disorders, especially acute lymphoblastic leukemia (ALL).
  • Preliminary studies have described a high incidence of childhood leukemia in these countries; however, no molecular analyses of these malignancies have yet been carried out.
  • We studied diagnostic samples from 84 patients from the National Children's Hospital in San Jose, Costa Rica (65 precursor B-ALL, 5 T-cell ALL, and 14 acute myeloblastic leukemia).
  • The observed rate of leukemia was 52.2 cases per million children per year.
  • None of the T-cell ALL cases were positive for either SIL-TAL1 or HOX11L2.
  • Within 14 acute myeloblastic leukemia patients, we confirmed 2 cases with FLT3-internal tandem duplication+, 1 patient with AML1-ETO, and only 1 case carrying a PML-RARalpha rearrangement.
  • The present study confirms the relatively high incidence of pediatric leukemia in Costa Rica and constitutes the first report regarding the incidence of the main molecular alterations of childhood leukemia in our region.
  • [MeSH-major] Leukemia / epidemiology. Leukemia / genetics
  • [MeSH-minor] Acute Disease. Child. Costa Rica / epidemiology. Cytogenetic Analysis. Gene Rearrangement. Humans. Mutation. Oncogene Proteins, Fusion / analysis

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194200.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


76. Pérez-Durán P, de Yebenes VG, Ramiro AR: Oncogenic events triggered by AID, the adverse effect of antibody diversification. Carcinogenesis; 2007 Dec;28(12):2427-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two of these mechanisms, somatic hypermutation (SHM) and class switch recombination (CSR), are initiated by activation-induced cytidine deaminase (AID) upon antigen stimulation of mature B cells.
  • AID deaminates cytosines on the DNA of Ig genes thereby generating a lesion that can be processed into a mutation (SHM) or a DNA double-strand break followed by a recombination reaction (CSR).
  • Most lymphocyte neoplasias are originated from mature B cells and harbour hallmark chromosome translocations of lymphomagenic potential, such as the c-myc/IgH translocations found in Burkitt lymphomas.
  • In addition, evidence is accumulating that AID expression can be induced in B cells independently of the germinal centre environment, such as in response to some viral infections, and occasionally in non-B cells, at least in certain inflammation-associated neoplasic situations.
  • [MeSH-major] Antibodies / immunology. Cell Transformation, Neoplastic. Cytidine Deaminase / immunology
  • [MeSH-minor] Animals. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Chromosome Aberrations. Gene Rearrangement. Genes, Immunoglobulin / immunology. Germinal Center / immunology. Germinal Center / pathology. Humans. Immunoglobulin Class Switching. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / pathology. Recombination, Genetic. Somatic Hypermutation, Immunoglobulin. Tumor Suppressor Proteins / physiology

  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17804422.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Tumor Suppressor Proteins; EC 3.5.4.- / AICDA (activation-induced cytidine deaminase); EC 3.5.4.5 / Cytidine Deaminase
  • [Number-of-references] 88
  •  go-up   go-down


77. Gomez S, Uribe S, Onetto JE, Emilson CG: SEM analysis of sealant penetration in posterior approximal enamel carious lesions in vivo. J Adhes Dent; 2008 Feb;10(2):151-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Each tooth was randomly assigned to mesial or distal surface application of a sealant in the lesion area and in surrounding sound enamel, with or without a bonding system.
  • Four groups were analyzed: a nonbonding group in the lesion area (NBL); a nonbonding group in sound enamel (NBS); a bonding group in the lesion area (BL) and a bonding group in sound enamel (BS).
  • CONCLUSION: The use of a bonding system prior to the application of a pit and fissure sealant on both lesion and sound enamel areas does not increase the resin penetration length under non-contaminated conditions.

  • MedlinePlus Health Information. consumer health - Tooth Decay.
  • Hazardous Substances Data Bank. HYDROGEN CHLORIDE .
  • Hazardous Substances Data Bank. SODIUM FLUORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18512513.001).
  • [ISSN] 1461-5185
  • [Journal-full-title] The journal of adhesive dentistry
  • [ISO-abbreviation] J Adhes Dent
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cariostatic Agents; 0 / Clinpro Sealant; 0 / Composite Resins; 0 / Dentin-Bonding Agents; 0 / Fluorides, Topical; 0 / Organophosphonates; 0 / Pit and Fissure Sealants; 0 / Scotchbond etchant; 0 / single bond; 0 / sodium fluoride topical preparation; 454I75YXY0 / Bisphenol A-Glycidyl Methacrylate; 8ZYQ1474W7 / Sodium Fluoride; QTT17582CB / Hydrochloric Acid
  •  go-up   go-down


78. Grimbert P, Mansour H, Desvaux D, Roudot-Thoraval F, Audard V, Dahan K, Berrehar F, Dehoulle-Poillet C, Farcet JP, Lang P, Le Gouvello S: The regulatory/cytotoxic graft-infiltrating T cells differentiate renal allograft borderline change from acute rejection. Transplantation; 2007 Feb 15;83(3):341-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The regulatory/cytotoxic graft-infiltrating T cells differentiate renal allograft borderline change from acute rejection.
  • The interpretation of cellular infiltrate from renal transplant recipients with borderline (BL) changes is still a challenging problem.
  • To analyze the immune phenotype of such infiltrate, we quantified the mRNA expression of Foxp3 and interleukinL-10 and granzyme B (GB) in 15 kidney biopsies with BL changes.
  • Controls were patients presenting type IA acute rejection and nonrejecting patients.
  • Levels of Foxp3 mRNA in BL changes were intermediate between type IA acute rejection and nonrejecting controls.
  • BL changes T cells infiltrate expressed a significantly higher Foxp3/GB ratio than that in IA acute rejection.
  • These results suggest that T cell infiltrate from BL change exhibit a tolerogenic rather than a cytotoxic phenotype.

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17297410.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / RNA, Messenger; 130068-27-8 / Interleukin-10; EC 3.4.21.- / Granzymes
  •  go-up   go-down


79. Anderson LA, Pfeiffer R, Warren JL, Landgren O, Gadalla S, Berndt SI, Ricker W, Parsons R, Wheeler W, Engels EA: Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev; 2008 Nov;17(11):3069-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HCV was associated with increased risk of diffuse large B-cell lymphoma [odds ratio (OR) 1.52, 95% confidence interval (95% CI) 1.05-2.18], Burkitt lymphoma (OR 5.21, 95% CI 1.62-16.8), follicular lymphoma (OR 1.88, 95% CI 1.17-3.02), marginal zone lymphoma (OR 2.20, 95% CI 1.22-3.95), and acute myeloid leukemia (OR 1.54, 95% CI 1.00-2.37).
  • Alcoholic hepatitis was associated with decreased risk of non-Hodgkin lymphoma overall, but increased risk of Burkitt lymphoma.
  • In summary, HCV, but not other causes of hepatitis, was associated with the elevated risk of non-Hodgkin lymphoma and acute myeloid leukemia.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1999 Nov;107(2):353-6 [10583224.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3388-94 [18239085.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Feb;16(2):215-9 [11207904.001]
  • [Cites] Eur J Clin Invest. 2001 Jul;31(7):628-38 [11454019.001]
  • [Cites] Acta Haematol. 2001;105(4):237-40 [11528098.001]
  • [Cites] Liver. 2001 Oct;21(5):335-41 [11589770.001]
  • [Cites] Jpn J Cancer Res. 2002 May;93(5):471-7 [12036441.001]
  • [Cites] Alcohol. 2002 May;27(1):17-21 [12062632.001]
  • [Cites] N Engl J Med. 2002 Jul 11;347(2):89-94 [12110736.001]
  • [Cites] Eur J Clin Nutr. 2002 Aug;56 Suppl 3:S50-3 [12142963.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Hematol J. 2003;4(5):303-9 [14502253.001]
  • [Cites] J Med Microbiol. 2004 Jan;53(Pt 1):21-9 [14663101.001]
  • [Cites] Haematologica. 2004 Jan;89(1):70-6 [14754608.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):425-30 [15006919.001]
  • [Cites] Med Oncol. 2004;21(1):67-72 [15034216.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):81-5 [15185347.001]
  • [Cites] Cancer Sci. 2004 Sep;95(9):745-52 [15471561.001]
  • [Cites] Gastroenterology. 1991 Jan;100(1):182-8 [1983820.001]
  • [Cites] Haematologica. 1996 Mar-Apr;81(2):162-4 [8641648.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Mar;5(3):227-30 [8833624.001]
  • [Cites] Hum Pathol. 1997 Jan;28(1):101-4 [9013840.001]
  • [Cites] Arch Virol. 1997;142(3):545-55 [9349300.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3328-37 [9787170.001]
  • [Cites] Science. 1998 Oct 30;282(5390):938-41 [9794763.001]
  • [Cites] Am J Public Health. 1999 Jan;89(1):14-8 [9987458.001]
  • [Cites] Leuk Lymphoma. 1999 Jun;34(1-2):45-52 [10350331.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1476-82 [10424754.001]
  • [Cites] Eur J Haematol. 2005 Feb;74(2):158-65 [15654908.001]
  • [Cites] Hepatology. 2005 Mar;41(3):652-9 [15723449.001]
  • [Cites] Expert Opin Drug Saf. 2005 May;4(3):599-608 [15934864.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8 [18387498.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):469-76 [15992695.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18544-9 [16339892.001]
  • [Cites] Haematologica. 2006 Apr;91(4):554-7 [16585021.001]
  • [Cites] J Hepatol. 2006 Aug;45(2):197-203 [16684579.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2078-85 [17119031.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):401-4 [17337646.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1360-4 [17326056.001]
  • [Cites] JAMA. 2007 May 9;297(18):2010-7 [17488966.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Hepatology. 2007 Jul;46(1):107-12 [17526021.001]
  • [Cites] Eur J Haematol. 2007 Aug;79(2):132-7 [17635237.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):791-8 [17941950.001]
  • [Cites] J Hepatol. 1999;31 Suppl 1:88-91 [10622567.001]
  • (PMID = 18957521.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010150-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS65580; NLM/ PMC2597453
  •  go-up   go-down


80. Ermakov S, Malkin I, Keter M, Kobyliansky E, Livshits G: Family-based association study of polymorphisms in the RUNX2 locus with hand bone length and hand BMD. Ann Hum Genet; 2008 Jul;72(Pt 4):510-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This research was aimed to test the hypothesis of association of radiographic hand bone length (BL) and BMD with polymorphisms in the RUNX2 locus.
  • These SNPs and four pairwise haplotypes were tested for association with eight BL and BMD traits, adjusted for covariates.
  • We observed significant associations between polymorphisms linked to the RUNX2 P1 promoter and BL mean values for three studied bone groups: all 18 bones, proximal and medial bones (p = 0.0118, 0.0085, and 0.0056, respectively).
  • Associations with BL and BMD mean values for medial and proximal bones remained significant even after correction for multiple testing.
  • This study provides evidence of the association between polymorphisms linked to the two RUNX2 promoters and variability of hand BL and BMD.
  • [MeSH-major] Bone Density. Core Binding Factor Alpha 1 Subunit / genetics. Genetic Predisposition to Disease. Hand Bones / chemistry. Osteoporosis / genetics. Polymorphism, Single Nucleotide

  • MedlinePlus Health Information. consumer health - Bone Density.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18373722.001).
  • [ISSN] 0003-4800
  • [Journal-full-title] Annals of human genetics
  • [ISO-abbreviation] Ann. Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 1 Subunit; 0 / RUNX2 protein, human
  •  go-up   go-down


81. Bai RX, Li P: [Influence of mild moxibustion on androgenic hormone in male rats with partial androgen deficiency]. Zhen Ci Yan Jiu; 2007 Aug;32(4):229-33, 236
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Thirty male SD rats (aged 12 months) were randomized into control, androlin (testosterone propionate) and moxibustion ["Shenshu" (BL 23), "Mingmen" (GV 4) and 'Guanyuan" (CV 4)] groups.

  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17907383.001).
  • [ISSN] 1000-0607
  • [Journal-full-title] Zhen ci yan jiu = Acupuncture research
  • [ISO-abbreviation] Zhen Ci Yan Jiu
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Androgens; 3XMK78S47O / Testosterone; WI93Z9138A / Testosterone Propionate
  •  go-up   go-down


82. Moormann AM, Heller KN, Chelimo K, Embury P, Ploutz-Snyder R, Otieno JA, Oduor M, Münz C, Rochford R: Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses. Int J Cancer; 2009 Apr 1;124(7):1721-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses.
  • Endemic Burkitt lymphoma (eBL) is the most common childhood cancer in equatorial Africa and is linked to Epstein-Barr virus (EBV) and Plasmodium falciparum coinfections early in life.
  • Epstein-Barr nuclear antigen 1 (EBNA1) is the sole viral latent antigen expressed in BL tumors.
  • Therefore, EBNA1-specific T cell responses were analyzed by IFN-gamma ELISPOT in Kenyan children with eBL and compared to healthy children with divergent malaria exposure.
  • CD8(+) T cell responses to EBV lytic and latent antigens not expressed in the tumors were similarly robust in eBL patients compared to healthy children.
  • In addition, CD4(+) T cell responses to a malaria protein, merozoite surface protein 1, were present in lymphoma patients.
  • This study demonstrates a selective loss of EBNA1-specific T cell responses in children with eBL and suggests a potential immunotherapeutic target for this EBV-associated lymphoma.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):461-73 [11313005.001]
  • [Cites] J Immunol. 2008 Feb 1;180(3):1451-61 [18209040.001]
  • [Cites] Science. 2003 Sep 5;301(5638):1371-4 [12958359.001]
  • [Cites] J Virol. 2003 Nov;77(22):12088-104 [14581546.001]
  • [Cites] Infect Immun. 2003 Dec;71(12):6766-74 [14638762.001]
  • [Cites] J Exp Med. 2004 Feb 16;199(4):459-70 [14769850.001]
  • [Cites] Tissue Antigens. 2004 Apr;63(4):293-325 [15009803.001]
  • [Cites] IARC Sci Publ. 1985;(60):165-76 [2998987.001]
  • [Cites] Nature. 1995 Jun 22;375(6533):685-8 [7540727.001]
  • [Cites] Immunity. 1997 Dec;7(6):791-802 [9430224.001]
  • [Cites] Nature. 1999 Jul 1;400(6739):73-7 [10403251.001]
  • [Cites] East Afr Med J. 2004 Aug;(8 Suppl):S68-77 [15622605.001]
  • [Cites] J Infect Dis. 2005 Apr 15;191(8):1233-8 [15776368.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3166-74 [16014568.001]
  • [Cites] Nat Immunol. 2006 Feb;7(2):165-72 [16415871.001]
  • [Cites] J Clin Microbiol. 2006 Apr;44(4):1459-67 [16597877.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):121-7 [17019706.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1138-46 [16985171.001]
  • [Cites] J Infect Dis. 2007 Mar 15;195(6):799-808 [17299709.001]
  • [Cites] J Immunol. 2002 Aug 1;169(3):1593-603 [12133989.001]
  • (PMID = 19089927.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108609; United States / NIAID NIH HHS / AI / AI4390; United States / FIC NIH HHS / TW / D43 TW006576; United States / NCI NIH HHS / CA / R01 CA101741; United States / NIAID NIH HHS / AI / U01 AI043906; United States / NIAID NIH HHS / AI / R01 AI043906; United States / NCI NIH HHS / CA / R01 CA134051; United States / NIAID NIH HHS / AI / K08 AI051565; United States / NCI NIH HHS / CA / CA101741; United States / FIC NIH HHS / TW / D43 TW006576-05; United States / NIAID NIH HHS / AI / K08-AI51565; United States / NIAID NIH HHS / AI / K08 AI051565-05; United States / NCI NIH HHS / CA / CA108609; United States / NCI NIH HHS / CA / R01 CA102667
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-encoded nuclear antigen 1; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Immunoglobulin G; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS98574; NLM/ PMC2708320
  •  go-up   go-down


83. Atapattu DN, Czuprynski CJ: Mannheimia haemolytica leukotoxin induces apoptosis of bovine lymphoblastoid cells (BL-3) via a caspase-9-dependent mitochondrial pathway. Infect Immun; 2005 Sep;73(9):5504-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mannheimia haemolytica leukotoxin induces apoptosis of bovine lymphoblastoid cells (BL-3) via a caspase-9-dependent mitochondrial pathway.
  • Mannheimia haemolytica is a key pathogen in the bovine respiratory disease complex.
  • It produces a leukotoxin (LKT) that is an important virulence factor, causing cell death in bovine leukocytes.
  • The LKT binds to the beta(2) integrin CD11a/CD18, which usually activates signaling pathways that facilitate cell survival.
  • In this study, we investigated mechanisms by which LKT induces death in bovine lymphoblastoid cells (BL-3).
  • Incubation of BL-3 cells with a low concentration of LKT results in the activation of caspase-3 and caspase-9 but not caspase-8.
  • These data suggest that LKT induces apoptosis of BL-3 cells via a caspase-9-dependent mitochondrial pathway.
  • Furthermore, scanning electron micrographs of mitochondria from LKT-treated BL-3 cells revealed lesions in the outer mitochondrial membrane, which are larger than previous reports of the permeability transition pore through which cytochrome c is usually released.
  • [MeSH-minor] Animals. Caspase 3. Caspase 8. Caspase 9. Cattle. Cell Line, Transformed. Cytochromes c / metabolism. Cytotoxins / physiology. Down-Regulation. L-Lactate Dehydrogenase / metabolism. Membrane Potentials / drug effects. Up-Regulation. Virulence Factors / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Biol. 1999 Feb 11;9(3):147-50 [10021389.001]
  • [Cites] FEMS Microbiol Lett. 1999 Oct 1;179(1):161-7 [10481101.001]
  • [Cites] Nature. 1999 Sep 2;401(6748):33-4 [10485701.001]
  • [Cites] Mol Microbiol. 1999 Sep;33(6):1190-9 [10510233.001]
  • [Cites] Infect Immun. 2000 Jan;68(1):72-9 [10603370.001]
  • [Cites] Am J Vet Res. 2000 Jan;61(1):51-6 [10630778.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):577-82 [10639121.001]
  • [Cites] Front Biosci. 2000 Apr 1;5:D438-51 [10762594.001]
  • [Cites] Trends Cell Biol. 2000 Sep;10(9):369-77 [10932094.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1150-1 [10970229.001]
  • [Cites] Cell Res. 2000 Sep;10(3):213-20 [11032173.001]
  • [Cites] Am J Vet Res. 2001 Jan;62(1):136-41 [11197552.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):505-13 [11228543.001]
  • [Cites] Mol Cell Neurosci. 2001 Apr;17(4):761-7 [11312610.001]
  • [Cites] Nat Struct Biol. 2001 May;8(5):394-401 [11323712.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27432-40 [11369777.001]
  • [Cites] Infect Immun. 2001 Oct;69(10):6131-9 [11553552.001]
  • [Cites] Curr Biol. 2001 Oct 2;11(19):R767-8 [11591332.001]
  • [Cites] Genes Dev. 2001 Nov 15;15(22):2922-33 [11711427.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):33024-34 [15166238.001]
  • [Cites] J Mol Histol. 2004 Jan;35(1):11-9 [15323345.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Sep;5(9):752-62 [15340382.001]
  • [Cites] Acta Chem Scand B. 1979;B33(2):93-9 [219645.001]
  • [Cites] J Vet Intern Med. 1992 Jan-Feb;6(1):11-22 [1548621.001]
  • [Cites] Eur J Immunol. 1993 Aug;23(8):1859-65 [8344347.001]
  • [Cites] Infect Immun. 1995 Aug;63(8):3209-12 [7622250.001]
  • [Cites] Infect Immun. 1996 Jul;64(7):2687-94 [8698496.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1132-6 [9027315.001]
  • [Cites] Infect Immun. 1997 Sep;65(9):3719-24 [9284143.001]
  • [Cites] Cell. 1997 Oct 17;91(2):231-41 [9346240.001]
  • [Cites] Am J Physiol. 1998 May;274(5 Pt 2):R1376-83 [9612405.001]
  • [Cites] Trends Cell Biol. 1998 Jul;8(7):267-71 [9714597.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1235-46 [9694712.001]
  • [Cites] FEBS Lett. 1998 Nov 13;439(1-2):168-72 [9849900.001]
  • [Cites] Microb Pathog. 1998 Dec;25(6):317-31 [9895270.001]
  • [Cites] EMBO J. 2001 Dec 3;20(23):6627-36 [11726499.001]
  • [Cites] Acta Oncol. 2001;40(6):696-701 [11765063.001]
  • [Cites] Vet Microbiol. 2002 Feb 4;84(4):337-56 [11750142.001]
  • [Cites] Nature. 2002 May 2;417(6884):99-102 [11986672.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Apr 26;293(1):349-55 [12054607.001]
  • [Cites] J Immunol. 2002 Jun 15;168(12):6330-5 [12055249.001]
  • [Cites] Infect Immun. 2002 Aug;70(8):4336-43 [12117943.001]
  • [Cites] Infect Immun. 2002 Sep;70(9):5058-64 [12183553.001]
  • [Cites] Anim Health Res Rev. 2002 Dec;3(2):69-82 [12665107.001]
  • [Cites] Cell Death Differ. 2003 Mar;10(3):335-44 [12700633.001]
  • [Cites] Am J Nephrol. 2003 May-Jun;23(3):140-51 [12624487.001]
  • [Cites] J Am Soc Nephrol. 2003 Jun;14(6):1427-34 [12761242.001]
  • [Cites] J Neurochem. 2003 Aug;86(3):591-604 [12859673.001]
  • [Cites] Mol Cell Biochem. 2004 Jan-Feb;256-257(1-2):141-55 [14977177.001]
  • [Cites] Exp Cell Res. 2004 Mar 10;294(1):106-17 [14980506.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 May;286(5):C1109-17 [15075210.001]
  • [Cites] J Biol Chem. 2004 Apr 16;279(16):16194-205 [14960575.001]
  • [Cites] Cancer Lett. 2004 Jul 16;210(2):139-50 [15183529.001]
  • (PMID = 16113266.001).
  • [ISSN] 0019-9567
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytotoxins; 0 / Exotoxins; 0 / Virulence Factors; 0 / leukotoxin; 9007-43-6 / Cytochromes c; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC1231077
  •  go-up   go-down


84. Kusao I, Agsalda M, Troelstrup D, Villanueva N, Shiramizu B: Chemotoxicity recovery of mitochondria in non-Hodgkin lymphoma resulting in minimal residual disease. Pediatr Blood Cancer; 2008 Aug;51(2):193-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotoxicity recovery of mitochondria in non-Hodgkin lymphoma resulting in minimal residual disease.
  • BACKGROUND: The mechanisms responsible for resistant disease or recurrence of non-Hodgkin lymphoma (NHL) in children cover a wide spectrum from drug resistance to genetic mutations.
  • A unique mechanism suggesting the role of mitochondria as the key energy source is studied following a clinical observation where pediatric Burkitt lymphoma (BL) specimens from patients on therapy were found to have increased copies of mitochondria DNA (mtDNA) in specimens which were shown to be positive for minimal residual disease and/or persistent disease (MRD/PD).
  • This study hypothesized that the mitochondria play an important role in a cell's recovery from toxicity via a compensatory increase in mtDNA.
  • PROCEDURE: BL specimens with MRD/PD were assayed for mtDNA.
  • An in vitro model was then designed using Ramos cell lines by exposing the lymphoma cells to varying concentrations of doxorubicin and vincristine for 1 hr; and allowing for recovery in culture over 7 days.
  • RESULTS: Increased mtDNA copy numbers were found in clinical specimens with MRD/PD as well as in recovering Ramos cells from chemotoxicity.
  • CONCLUSIONS: The recovering lymphoma cells from the chemotoxic effects appeared to compensate by increasing mtDNA content, which may contribute to the clinical residual or resistant disease in some cases of childhood BL.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1999 Nov;13(11):1691-5 [10557040.001]
  • [Cites] Vopr Onkol. 2006;52(4):398-403 [17024810.001]
  • [Cites] Forensic Sci Int. 2002 Mar 28;126(1):34-9 [11955829.001]
  • [Cites] Int J Oncol. 2002 Dec;21(6):1339-45 [12429986.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Feb;25(2):109-13 [12571460.001]
  • [Cites] Br J Haematol. 2003 Feb;120(4):660-70 [12588354.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1437-47 [12886229.001]
  • [Cites] Leuk Res. 2003 Dec;27(12):1109-13 [12921949.001]
  • [Cites] Semin Oncol. 1980 Sep;7(3):332-9 [7414342.001]
  • [Cites] FEBS Lett. 1995 Oct 16;373(3):285-90 [7589484.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8512-5 [15623632.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Apr;37(4):822-34 [15694841.001]
  • [Cites] Mol Interv. 2005 Apr;5(2):94-111 [15821158.001]
  • [Cites] Gynecol Oncol. 2005 Jul;98(1):104-10 [15921730.001]
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):920-4 [15856456.001]
  • [Cites] Antivir Ther. 2005;10 Suppl 2:M83-9 [16152709.001]
  • [Cites] Cell Mol Biol Lett. 2005;10(4):721-32 [16341280.001]
  • [Cites] Eur J Cancer. 2006 Feb;42(3):295-309 [16324833.001]
  • [Cites] Genet Mol Res. 2006;5(1):55-62 [16755497.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1455-9 [17627010.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1271-7 [17456722.001]
  • [Cites] Mini Rev Med Chem. 2007 Oct;7(10):1035-9 [17979806.001]
  • [Cites] Oncogene. 2008 Jan 31;27(6):831-8 [17637738.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4647-62 [16892079.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1797-803 [10688840.001]
  • (PMID = 18322926.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA121955; United States / NCI NIH HHS / CA / R21 CA121955; United States / NCI NIH HHS / CA / R21 CA121955-01; United States / NCI NIH HHS / CA / CA121955-01; United States / NCI NIH HHS / CA / R21 CA121955-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Mitochondrial; 8L70Q75FXE / Adenosine Triphosphate
  • [Other-IDs] NLM/ NIHMS95130; NLM/ PMC2652580
  •  go-up   go-down


85. Fellows EA, Keene FR: Influence of anions on intervalence charge transfer (IVCT) in mixed-valence dinuclear complexes. J Phys Chem B; 2007 Jun 21;111(24):6667-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Spectroelectrochemical studies of the intervalence charge transfer (IVCT) characteristics of both diastereoisomeric forms of the dinuclear complex [{Ru(bpy)2}2(mu-dpi-)]n+ [bpy=2,2'-bipyridine; dpi-=4,5-di(2-pyridyl)imidazolate] showed that the degree of inter-metal electronic coupling (or valence delocalization) is dependent on stereochemical identity.
  • In a comparative investigation of electrochemical and spectroelectrochemical techniques of the anion-induced electron localization in [{Ru(bpy)2}2(mu-dpo)]5+ [dpo=3,4-di(2-pyridyl)-1,2,5-oxadiazole], differences were observed between the two methods in the order and extent of effects induced by a number of inorganic anions (PF6-, BF4-, ClO4-).
  • Comparative electrochemical studies were undertaken on [{M(bpy)2}2(mu-BL)]n+ {M=Ru, Os; BL=dpo, dpi-), which revealed substantial differences in DeltaEox (the separation between the redox potentials for the MII-MII/MIII-MII and MII-MIII/MIII-MIII couples) for the two metal centers and therefore the comproportionation constant Kc, dependent on the neutral or anionic nature of the bridging ligand.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17388473.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Nileshwar A, Garg V: Comparison of Bullard laryngoscope and short-handled Macintosh laryngoscope for orotracheal intubation in pediatric patients with simulated restriction of cervical spine movements. Paediatr Anaesth; 2010 Dec;20(12):1092-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of Bullard laryngoscope and short-handled Macintosh laryngoscope for orotracheal intubation in pediatric patients with simulated restriction of cervical spine movements.
  • AIM: To compare time to intubation, time to optimal laryngoscopy, best laryngeal view, and success rate of intubation with pediatric Bullard laryngoscope and short-handled Macintosh laryngoscope in children being intubated with neck stabilization.
  • BACKGROUND: Securing airway of a patient with restricted cervical spine movement has been a challenge faced by anaesthesiologists around the world.
  • Macintosh laryngoscope with manual inline stabilization is most commonly used.
  • Bullard laryngoscope is also useful in this situation as minimal neck movement occurs with its use.
  • Patients were randomly allocated to one of two groups: Group MB (first laryngoscopy using short-handled Macintosh laryngoscope followed by pediatric Bullard laryngoscope) and Group BM (first laryngoscopy using pediatric Bullard laryngoscope followed by short-handled Macintosh laryngoscope) with manual inline stabilization after induction of anesthesia and paralysis.
  • RESULTS: Laryngeal view when obtained was always Grade 1 with Bullard laryngoscope (38/38) when compared to Macintosh laryngoscope [Grade 1 (10/40)].
  • The mean time to laryngoscopy (and intubation) was shorter with Macintosh laryngoscope [15.53 s (38.15 s)] than Bullard laryngoscope [35.21 s (75.71 s)], respectively.
  • Success rate of intubation was higher with Macintosh laryngoscope (100%) when compared to Bullard laryngoscope (70%).
  • CONCLUSIONS: Laryngoscopy and intubation is faster using a short-handled Macintosh laryngoscope with a higher success rate compared to pediatric Bullard laryngoscope in pediatric patients when manual inline stabilization is applied.
  • [MeSH-major] Immobilization. Intubation, Intratracheal / instrumentation. Laryngoscopes. Laryngoscopy / instrumentation

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 21199118.001).
  • [ISSN] 1460-9592
  • [Journal-full-title] Paediatric anaesthesia
  • [ISO-abbreviation] Paediatr Anaesth
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] France
  •  go-up   go-down


87. Omoregie FO, Saheeb BD, Onasanya PO: Periradicular burkitt's lymphoma: a report of 2 cases from Nigeria and review of the literature. Afr J Med Med Sci; 2008 Sep;37(3):279-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periradicular burkitt's lymphoma: a report of 2 cases from Nigeria and review of the literature.
  • This article reports two cases of periradicular Burkitt's lymphoma from Nigeria, to emphasize the difficulties in differentiating the early lesion from other periradicular lesions with similar clinical and radiological findings Case 1, is a 4-year-old boy who presented with a one-month history of a painless, hard, posterior mandibular swelling (right), which was causing loosening and displacement of deciduous teeth (84 and 85).
  • Histopathological examination of periradicular tissues from extracted tooth (85), confirmed the diagnosis of early periradicular B urkitt's lymphoma.
  • Case 2, is a 6-year-old boy who presented with one-week history of a loose, extruded right mandibular first molar tooth (46) and an exfoliated left mandibular first molar tooth (36).
  • Incisional biopsy of the oral lesion at the region of exfoliated left first mandibular molar (36) was useful for histopathological diagnosis of early Burkitt's lymphoma of the jaw.
  • In the face of limited diagnostic tools such as clinico-radiological assessment, cytology or incisional biopsy for incipient periradicular lesions, a high index of suspicion of Burkitt's lymphoma of the jaw may be helpful in early diagnosis and treatment of a lesion, presenting in a child as periradicular radiolucency or mixed radiolucency and radiopacity, with associated loosening and displacement of teeth.
  • [MeSH-major] Burkitt Lymphoma / pathology. Jaw Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy. Child. Child, Preschool. Diagnosis, Differential. Fatal Outcome. Humans. Male

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18982822.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


88. Zainina S, Cheong SK: Myelodysplastic syndrome transformed into Acute Lymphoblastic Leukaemia (FAB:L3). Clin Lab Haematol; 2006 Aug;28(4):282-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelodysplastic syndrome transformed into Acute Lymphoblastic Leukaemia (FAB:L3).
  • Myelodysplastic syndrome (MDS) is recognized as a preleukaemic disorder with a variable risk of transformation to acute myeloid leukaemia.
  • Usually the blast cells in leukaemia are transformed after MDS displays a myeloid phenotype.
  • Even though lymphoid progression had been reported previously, most displayed myeloid-lymphoid hybrid or early B phenotype.
  • We report a case of an elderly man who had MDS transformed into Acute Lymphoblastic Leukaemia (ALL:L3) which is a rare lymphoid transformation.
  • [MeSH-major] Anemia, Refractory / pathology. Burkitt Lymphoma / pathology. Cell Transformation, Neoplastic / pathology


89. Clybouw C, Hadji A, ElMchichi B, Auffredou MT, Leca G, Vazquez A: BimL upregulation induced by BCR cross-linking in BL41 Burkitt's lymphoma results from a splicing mechanism of the BimEL mRNA. Biochem Biophys Res Commun; 2009 May 22;383(1):32-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BimL upregulation induced by BCR cross-linking in BL41 Burkitt's lymphoma results from a splicing mechanism of the BimEL mRNA.
  • Indeed, expression of a BimEL cDNA leads in Hela cells leads to the production of both BimEL and BimL proteins.
  • [MeSH-major] Apoptosis Regulatory Proteins / genetics. Burkitt Lymphoma / genetics. Gene Expression Regulation, Leukemic. Membrane Proteins / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-bcr / metabolism. RNA Splicing
  • [MeSH-minor] Cell Line, Tumor. Humans. Introns / genetics. Protein Biosynthesis / genetics. RNA, Messenger / genetics. Up-Regulation

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19332026.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Bcl-2-like protein 11; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; EC 2.7.11.1 / BCR protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-bcr
  •  go-up   go-down


90. Moffett PM, Baker BL, Kang CS, Johnson MS: Evaluation of time required for water-only decontamination of an oil-based agent. Mil Med; 2010 Mar;175(3):185-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After 30 sec a black light was used by three evaluators to determine whether the agent was removed.
  • CONCLUSION: Whereas the data suggest the possibility of rapid water-only decontamination, the applicability of this data in current form is doubtful, but provides a model as a basis for future study.

  • MedlinePlus Health Information. consumer health - Biodefense and Bioterrorism.
  • MedlinePlus Health Information. consumer health - Chemical Emergencies.
  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20358708.001).
  • [ISSN] 0026-4075
  • [Journal-full-title] Military medicine
  • [ISO-abbreviation] Mil Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemical Warfare Agents; 0 / Oils; 059QF0KO0R / Water
  •  go-up   go-down


91. Meng JY, Zhang CY, Lei CL: A proteomic analysis of Helicoverpa armigera adults after exposure to UV light irradiation. J Insect Physiol; 2010 Apr;56(4):405-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A proteomic analysis of Helicoverpa armigera adults after exposure to UV light irradiation.
  • Ultraviolet (UV) light (blacklight), which emits UV in the range of 320-400nm, has been used worldwide in light trapping of insect pests.
  • To gain a better understanding of the response of Helicoverpa armigera adults to UV light irradiation, we carried out a comparative proteomic analysis.
  • Three-day-old adults were exposed to UV light for 1h.
  • This study is the first analysis of differentially expressed proteins in phototactic insects under UV light irradiation conditions and gives new insights into the adaptation mechanisms responsive to UV light irradiation stress.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19944107.001).
  • [ISSN] 1879-1611
  • [Journal-full-title] Journal of insect physiology
  • [ISO-abbreviation] J. Insect Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Insect Proteins
  •  go-up   go-down


92. Kimura M, Kagawa T: Blue light-induced chloroplast avoidance and phototropic responses exhibit distinct dose dependency of PHOTOTROPIN2 in Arabidopsis thaliana. Photochem Photobiol; 2009 Sep-Oct;85(5):1260-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blue light-induced chloroplast avoidance and phototropic responses exhibit distinct dose dependency of PHOTOTROPIN2 in Arabidopsis thaliana.
  • PHOTOTROPIN2 (PHOT2) is a unique photoreceptor involved in chloroplast avoidance movement and also regulates blue light (BL) responses, such as phototropism and leaf flattening, together with PHOTOTROPIN1 (PHOT1) in Arabidopsis thaliana.
  • In the present study, we examined PHOT2 dose dependency of BL responses using the phot1-5 phot2-1 double mutant expressing an AtPHOT2-GFP (P2G) fusion protein.
  • Chloroplast avoidance and phototropic responses of P2G transgenic lines were enhanced in a manner dependent on the P2G levels, whereas the leaf flattening phenotype was simply complemented by P2G equivalent to the wild type (WT) PHOT2 level.
  • The chloroplast avoidance velocity of P2G transgenic lines exhibited enhanced sensitivity to BL in comparison with WT.
  • These results collectively indicate that each BL response has distinct threshold levels of PHOT2 requirement.
  • [MeSH-major] Arabidopsis / physiology. Arabidopsis Proteins / physiology. Chloroplasts / physiology. Light

  • The Arabidopsis Information Resource. Linked Gene Data (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19453386.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arabidopsis Proteins
  •  go-up   go-down


93. Chen Y, Peng C, Li D, Li S: Molecular and cellular bases of chronic myeloid leukemia. Protein Cell; 2010 Feb;1(2):124-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular and cellular bases of chronic myeloid leukemia.
  • Chronic myeloid leukemia (CML) is a myeloproliferative disease characterized by the overproduction of granulocytes, which leads to high white blood cell counts and splenomegaly in patients.
  • Based on clinical symptoms and laboratory findings, CML is classified into three clinical phases, often starting with a chronic phase, progressing to an accelerated phase and ultimately ending in a terminal phase called blast crisis.
  • Blast crisis phase of CML is clinically similar to an acute leukemia; in particular, B-cell acute lymphoblastic leukemia (B-ALL) is a severe form of acute leukemia in blast crisis, and there is no effective therapy for it yet.
  • However, the inability of BCR-ABL kinase inhibitors to completely kill leukemia stem cells (LSCs) indicates that these kinase inhibitors are unlikely to cure CML.
  • [MeSH-major] Fusion Proteins, bcr-abl / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Neoplastic Stem Cells / enzymology. Neoplastic Stem Cells / pathology. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] 5-Lipoxygenase-Activating Proteins / metabolism. Animals. Benzamides. Disease Models, Animal. Humans. Imatinib Mesylate. Male. Mice. PTEN Phosphohydrolase / metabolism. Philadelphia Chromosome. Piperazines / therapeutic use. Point Mutation. Protein Structure, Tertiary. Pyrimidines / therapeutic use

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21203982.001).
  • [ISSN] 1674-8018
  • [Journal-full-title] Protein & cell
  • [ISO-abbreviation] Protein Cell
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 5-Lipoxygenase-Activating Proteins; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC4875160
  •  go-up   go-down


94. Murphy JJ, Tawfeeq M, Chang B, Nadel H: Early experience with PET/CT scan in the evaluation of pediatric abdominal neoplasms. J Pediatr Surg; 2008 Dec;43(12):2186-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has the potential to be a valuable tool in the evaluation of pediatric abdominal tumors.
  • These included Burkitt's lymphoma (8), neuroblastoma (7), rhabdomyosarcoma (6), ovarian tumor (3), Wilms' tumor (2), hepatocellular carcinoma (2), paraganglioma (1), germ cell tumor (1), undifferentiated sarcoma (1), renal primitive neuroectodermal tumor (1), gastrointestinal stromal tumor (1), adrenocortical carcinoma (1), inflammatory pseudotumor (1), and adrenal adenoma (1).
  • These include (1) preoperative staging, (2) selection of appropriate site for biopsy, (3) identification of occult metastatic disease, (4) follow-up for residual or recurrent disease, and (5) assessment of response to chemotherapy.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19040932.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


95. Karakayali H, Ozcay F, Sevmis S, Savas N, Haberal M: Liver transplantation for small babies. Transplant Proc; 2007 May;39(4):1153-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for small babies.
  • Orthotopic liver transplantation remains a major medical and surgical challenge in small pediatric patients.
  • From April 2003 to June 2006, 21 small babies (each of whom weighed less than 10 kg or was younger than 1 year of age) underwent orthotopic liver transplantation.
  • Histological examination revealed hepatocellular carcinoma in 2 patients, and Burkitt's lymphoma in 1 patient.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524918.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Yun HS, Bae YH, Lee YJ, Chang SC, Kim SK, Li J, Nam KH: Analysis of phosphorylation of the BRI1/BAK1 complex in arabidopsis reveals amino acid residues critical for receptor formation and activation of BR signaling. Mol Cells; 2009 Feb 28;27(2):183-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The formation of a receptor complex in response to BRs and the subsequent activation of cytoplasmic domain kinase activity share mechanistic characteristics with animal receptor kinases.
  • In addition, transgenic wild type plants overexpressing BAK1(T455A) lost the phosphorylation activity normally exhibited in response to BL, leading to semi-dwarfism.
  • [MeSH-minor] Agrobacterium tumefaciens / growth & development. Agrobacterium tumefaciens / metabolism. Amino Acid Substitution. Brassinosteroids. Cell Membrane / metabolism. Mutation / genetics. Phosphorylation. Plants, Genetically Modified. Plasmids. Saccharomyces cerevisiae / growth & development. Saccharomyces cerevisiae / metabolism

  • COS Scholar Universe. author profiles.
  • The Arabidopsis Information Resource. Linked Gene Data (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19277500.001).
  • [ISSN] 1016-8478
  • [Journal-full-title] Molecules and cells
  • [ISO-abbreviation] Mol. Cells
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Arabidopsis Proteins; 0 / Brassinosteroids; 0 / Cholestanols; 0 / Plant Growth Regulators; 0 / Steroids, Heterocyclic; EC 2.7.- / Protein Kinases; EC 2.7.1.- / BAK1 protein, Arabidopsis; EC 2.7.11.1 / BRI1 protein, Arabidopsis; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; Y9IQ1L53OX / brassinolide
  •  go-up   go-down


97. Li L, Gupta S, Bashir T, Koduru PR, Brody J, Allen SL: Serial cytogenetic alterations resulting in transformation of a low-grade follicular lymphoma to Burkitt lymphoma. Cancer Genet Cytogenet; 2006 Oct 15;170(2):140-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serial cytogenetic alterations resulting in transformation of a low-grade follicular lymphoma to Burkitt lymphoma.
  • Follicular lymphoma (FL) is the most common indolent or low-grade non-Hodgkin lymphoma (NHL).
  • Histologic transformation to high-grade lymphoma, generally to diffuse large B-cell lymphoma, occurs in 25-35% of cases.
  • We report the case of a 58-year-old patient who presented with stage IVA, grade 2 FL that subsequently transformed to Burkitt lymphoma.
  • A t(1;11)(q25;q13) was acquired simultaneously with t(8;22) and, in conjunction with other chromosomal abnormalities, coincided with an extremely aggressive clinical course.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosome Aberrations. Lymphoma, Follicular / genetics
  • [MeSH-minor] Bone Marrow / pathology. Chromosome Inversion. Disease Progression. Gene Rearrangement. Humans. Immunoglobulin Heavy Chains / genetics. Immunophenotyping. Lymph Nodes / pathology. Male. Middle Aged. Translocation, Genetic

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011985.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


98. Said J: Diffuse aggressive B-cell lymphomas. Adv Anat Pathol; 2009 Jul;16(4):216-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse aggressive B-cell lymphomas.
  • Diffuse aggressive B-cell lymphomas comprise a relatively common and increasingly diverse group of neoplasms.
  • At the same time there is increasing understanding of the overlap, which occurs in the grey zone between diffuse large B-cell lymphoma and Burkitt lymphoma as well as between diffuse large B-cell lymphoma and Hodgkin lymphoma.
  • This review aims to provide practical insights in the correct identification and differential diagnosis of these lymphomas, with emphasis on the changes that have occurred with the publication of the 2008 World Health Organization updated classification.
  • [MeSH-major] Biomarkers, Tumor. Burkitt Lymphoma / diagnosis. Hodgkin Disease / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Bone Marrow / pathology. Bone Marrow Examination. Diagnosis, Differential. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Herpesvirus 4, Human / isolation & purification. Humans. Immunohistochemistry. Predictive Value of Tests. Stromal Cells / pathology. World Health Organization

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19546610.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 147
  •  go-up   go-down


99. Motsch N, Pfuhl T, Mrazek J, Barth S, Grässer FA: Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) induces the expression of the cellular microRNA miR-146a. RNA Biol; 2007 Nov;4(3):131-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epstein-Barr Virus (EBV) infection induces cellular non-coding (nc)RNAs e.g., the "vault" RNAs or miRNAs such as miR-21, miR-155 or miR-146a.
  • MiR-146a is upregulated in various tumours and plays a role in innate immunity.
  • Northern blotting revealed high levels of miR-146a and miR-155 in the Burkitt's lymphoma cell line Jijoye which expresses LMP1 while the LMP1-deficient P3HR1 mutant derived from Jijoye expresses less miR-146a or miR-155.
  • Likewise, EBV-latency type I Burkitt's lymphoma cells with low LMP1 levels also contain low levels of either miR-146a or miR-155 while their levels are increased in LMP1-expressing EBV-latency type III BL cells.
  • It is possible that the induction of miR-146a plays a role in the induction or maintenance of EBV latency by modulating innate immune responses to the virus infected host cell.
  • [MeSH-minor] B-Lymphocytes / immunology. B-Lymphocytes / metabolism. B-Lymphocytes / virology. Base Sequence. Burkitt Lymphoma / immunology. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / virology. Cell Line. Cell Line, Transformed. Cell Line, Tumor. Humans. Molecular Sequence Data. NF-kappa B / physiology. Virus Latency / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347435.001).
  • [ISSN] 1555-8584
  • [Journal-full-title] RNA biology
  • [ISO-abbreviation] RNA Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / MIRN146 microRNA, human; 0 / MicroRNAs; 0 / NF-kappa B; 0 / Viral Matrix Proteins
  •  go-up   go-down


100. Liu HL, Chen Y, Cui GH, Wu QL, He J: Regulating expressions of cyclin D1, pRb, and anti-cancer effects of deguelin on human Burkitt's lymphoma Daudi cells in vitro. Acta Pharmacol Sin; 2005 Jul;26(7):873-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulating expressions of cyclin D1, pRb, and anti-cancer effects of deguelin on human Burkitt's lymphoma Daudi cells in vitro.
  • AIM: To investigate anticancer effects and molecular mechanism of deguelin on human Burkittos lymphoma Daudi cells in vitro and compare the cytotoxicities of deguelin on Daudi cells and human peripheral blood monocular cells (PBMC).
  • The effect of deguelin on the cell cycle of Daudi cells were studied by a propidium iodide method.
  • CONCLUSION: Deguelin is able to inhibit the proliferation of Daudi cells by regulating the cell cycle that arrested cells at G0/G1 phase and inducing the cell apoptosis.
  • [MeSH-major] Apoptosis. Burkitt Lymphoma / pathology. Cyclin D1 / metabolism. Retinoblastoma Protein / metabolism. Rotenone / analogs & derivatives
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / pharmacology. Cell Cycle / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Humans. Leukocytes, Mononuclear / cytology. Leukocytes, Mononuclear / drug effects. Leukocytes, Mononuclear / metabolism






Advertisement